EDX Medical Group plc (LON:EDX), which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, has announced the Company has appointed Dr Joanne Hackett and Mr Peter Collins as non-executive directors.
Dr Hackett and Mr Collins, who have been appointed with immediate effect, are highly experienced in the strategic planning and commercialisation of diagnostic and health care solutions.
Dr Hackett has global experience across academic, business and clinical institutions. She is Vice President and Global Head of Health System Services for IQVIA, a leading provider of clinical research services and commercial insights to the life sciences and healthcare industries. Previous appointments include chief commercial officer, Genomics England, chief commercial officer and interim CEO, Precision Medicine Catapult, Director of Commercial Development, UCL Partners and Strategy Lead, Pfizer Neusentis.
Mr Collins is a precision oncology and molecular diagnostics executive with a track record of identifying, building and commercialising breakthrough technologies across companion diagnostics, liquid biopsy, and molecular residual disease before widespread market adoption. He has held senior leadership roles at DxS, GSK, Guardant Health, Inivata, and SAGA Diagnostics, translating scientific innovation into clinically adopted, reimbursed and scalable products through business development, commercial strategy, market access, strategic partnerships and company building.
Dr Mike Owen, chairman of EDX Medical, commented: “We are delighted to welcome two outstanding industry figures in Joanne and Peter to the Board. They bring a wealth of experience which will serve the Company well.”
Professor Sir Chris Evans, founder and chief scientific officer, EDX Medical, commented: “Joanne and Peter are exceptional talents and their skills, particularly in the commercialising of companies will be a huge asset as we continue to build EDX Medical.”
Additional information
Dr Hackett aged 47 holds no ordinary shares in the Company.
Dr Hackett holds or has held the following directorships and/or partnerships in the past five years:
Current
IZY Capital Partners Limited
Reset Health Limited
Past
eLife Sciences Publications Limited
AgeX Therapeutics Inc
Seaport Topco Limited
Peter Collins aged 67 holds no ordinary shares in the Company.
Peter Collins has held the following directorships and/or partnerships in the past five years:
CellBxHealth plc
Saga Diagnostics UK Limited
Collins Biotech Consulting SRL
There is no further information required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.
